Innovative Therapeutics

Meems, Laura M.G.; Burnett, John C.

doi:10.1016/j.jacbts.2016.10.001

Cited by 44 publications

(16 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale behind using NPs as a therapeutic target in HF therapy [45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] resides in the seemingly abnormal BNP processing with a subsequent deficiency in active forms and resistance to their biological effects in these patients [5]. It seems that HF patients are deficient in biologically active BNP32 with a subsequent increase in BNP1–108 [45].…”

Section: Therapeutic Implications Of Natriuretic Peptides In Heartmentioning

confidence: 99%

Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications

Tănase

Radu

Shurbaji

et al. 2019

IJMS

View full text Add to dashboard Cite

The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its challenging diagnosis and management combines clinical, imagistic and biological data. Natriuretic peptides (NPs) are hormones secreted in response to myocardial stretch that, by increasing cyclic guanosine monophosphate (cGMP), counteract myocardial fibrosis and hypertrophy, increase natriuresis and determine vasodilatation. While their role in HFpEF is controversial, most authors focused on b-type natriuretic peptides (BNPs) and agreed that patients may show lower levels. In this setting, newer molecules with an increased specificity, such as middle-region pro-atrial natriuretic peptide (MR-proANP), emerged as promising markers. Augmenting NP levels, either by NP analogs or breakdown inhibition, could offer a new therapeutic target in HFpEF (already approved in their reduced EF counterparts) by increasing the deficient cGMP levels found in patients. Importantly, these peptides also retain their prognostic value. This narrative review focuses on NPs’ physiology, diagnosis, therapeutic and prognostic implication in HFpEF.

show abstract

Section: Therapeutic Implications Of Natriuretic Peptides In Heartmentioning

confidence: 99%

Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications

Tănase

Radu

Shurbaji

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Therefore, newer designer natriuretic peptides that differ from the native peptides in terms of efficacy, specificity, and resistance to enzymatic degradation have been developed. 40 Another option to augment the system is to attenuate natriuretic peptide clearance. However, neprilysin is a promiscuous enzyme that in addition to natriuretic peptides degrades many other substrates.…”

Section: Pharmacological Manipulation Of Natriuretic Peptide Signalingmentioning

confidence: 99%

Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk

et al. 2018

View full text Add to dashboard Cite

“…7 Moreover, novel anti-hypertensive agents targeting the ANP/BNP/GC-A pathway are in clinical development, including potent long-lasting ANP-based analogues, as well as sacubitril/valsartan in which one of its active components blocks the natriuretic peptide-degrading enzyme neprilysin (NEP). 8…”

Section: Editorialmentioning

confidence: 99%